NEW YORK (GenomeWeb News) – Response Genetics today said that it has regained compliance with the Nasdaq Capital Market's rule covering the minimum market value of listed securities.
The Los Angeles-based molecular diagnostics developer said that it was notified by Nasdaq on Feb. 16 that it had regained compliance and the "delisting matter is now closed."
Earlier this month, the firm raised more than $7.8 million from a private placement of roughly 5.3 million shares of common stock at $1.50 per share.
In early Tuesday trade, shares of Response Genetics rose 3 percent to $2.17.